Shigellosis Clinical Trial
Official title:
A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis With Shigella Flexneri 2a Strain
The study is a first-in-human Phase 1/2a randomized, double-blind, placebo-controlled trial to assess the clinical safety and efficacy of ShigActive in healthy adults with experimental Shigella challenge.
The purpose of this study is to determine if ShigActive is safe and effective in healthy adults in a continuous Phase 1/2a trial. Phase 1 will asses the safety of ShigActive in healthy adults, while Phase 2a will evaluate the safety and efficacy of ShigActive in healthy adults after a challenge with Shigella. ShigActive is a collection of bacteriophages. Bacteriophages (or phages) are viruses that infect only bacteria. The phages in ShigActive infect a specific type of bacteria called Shigella, which is the causative agent of shigellosis or dysentery. ShigActive is intended to significantly reduce or eliminate Shigella levels in the human gastrointestinal tract, which in turn, is anticipated to reduce the incidence and/or severity of shigellosis. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02797236 -
SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT04056117 -
A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05959616 -
Shigella Sonnei 53G Human Infection Study in Kenyan Adults
|
Phase 1 | |
Completed |
NCT02445963 -
Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)
|
Phase 1 | |
Not yet recruiting |
NCT05961059 -
InvaplexAR-Detox and dmLT Adjuvant in the Netherlands and Zambia
|
Phase 1 | |
Completed |
NCT00485134 -
Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection
|
Phase 1/Phase 2 | |
Completed |
NCT01369927 -
Shigella Sonnel O-SPC/rBRU Conjugate Vaccine
|
Phase 1 | |
Completed |
NCT02034500 -
Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults
|
Phase 1 | |
Completed |
NCT01509846 -
Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults
|
Phase 1 | |
Completed |
NCT02105714 -
Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders
|
N/A | |
Withdrawn |
NCT01399424 -
Shigella Sonnei OSPC-rDT Conjugate Vaccine
|
Phase 1 | |
Completed |
NCT00800930 -
Therapeutic Induction of Endogenous Antibiotics
|
Phase 2 | |
Completed |
NCT00368316 -
Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel
|
Phase 3 | |
Completed |
NCT02388009 -
Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a
|
Phase 1 | |
Completed |
NCT02017899 -
A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.
|
Phase 1 | |
Completed |
NCT01069471 -
Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella
|
Phase 1 | |
Completed |
NCT02646371 -
Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a
|
Phase 2 | |
Recruiting |
NCT05156528 -
Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years
|
Phase 3 | |
Completed |
NCT03854929 -
Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery
|
Phase 4 | |
Recruiting |
NCT05121974 -
Tebipenem Trial in Children With Shigellosis
|
Phase 2 |